schliessen

Filtern

 

Bibliotheken

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

BACKGROUND:: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated with lower adherence and potential resistance development. METHODS:: We enrolled HIV-infected, virologically... Full description

Journal Title: JAIDS Journal of Acquired Immune Deficiency Syndromes 2017, Vol.74(2), pp.193-200
Main Author: Huhn, D., Gregory
Other Authors: Tebas, M., Pablo , Gallant, W., Joel , Wilkin, W., Timothy , Cheng, W., Andrew , Yan, W., Mingjin , Zhong, W., Lijie , Callebaut, W., Christian , Custodio, W., Joseph , Fordyce, W., Marshall , Das, W., Moupali , Mccallister, W., Scott
Format: Electronic Article Electronic Article
Language:
Subjects:
Hiv
ID: ISSN: 1525-4135 ; DOI: 10.1097/QAI.0000000000001193
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ovid10.1097/QAI.0000000000001193
title: A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
format: Article
creator:
  • Huhn, D., Gregory
  • Tebas, M., Pablo
  • Gallant, W., Joel
  • Wilkin, W., Timothy
  • Cheng, W., Andrew
  • Yan, W., Mingjin
  • Zhong, W., Lijie
  • Callebaut, W., Christian
  • Custodio, W., Joseph
  • Fordyce, W., Marshall
  • Das, W., Moupali
  • Mccallister, W., Scott
subjects:
  • Clinical Science
  • Hiv
  • Regimen Simplification
  • Tenofovir Alafenamide
  • Darunavir
ispartof: JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017, Vol.74(2), pp.193-200
description: BACKGROUND:: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated with lower adherence and potential resistance development. METHODS:: We enrolled HIV-infected, virologically suppressed adults with 2-class to 3-class drug resistance and at least 2 prior regimen failures into this phase 3, open-label, randomized study. The primary endpoint was the percentage of participants with HIV-1 RNA
language:
source:
identifier: ISSN: 1525-4135 ; DOI: 10.1097/QAI.0000000000001193
fulltext: fulltext
issn:
  • 1525-4135
  • 15254135
url: Link


@attributes
ID1793850775
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1097/QAI.0000000000001193
sourceidovid
recordidTN_ovid10.1097/QAI.0000000000001193
sourceformatXML
sourcesystemPC
pqid1835451936
display
typearticle
titleA Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
creatorHuhn, D., Gregory ; Tebas, M., Pablo ; Gallant, W., Joel ; Wilkin, W., Timothy ; Cheng, W., Andrew ; Yan, W., Mingjin ; Zhong, W., Lijie ; Callebaut, W., Christian ; Custodio, W., Joseph ; Fordyce, W., Marshall ; Das, W., Moupali ; Mccallister, W., Scott
ispartofJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017, Vol.74(2), pp.193-200
identifierISSN: 1525-4135 ; DOI: 10.1097/QAI.0000000000001193
descriptionBACKGROUND:: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated with lower adherence and potential resistance development. METHODS:: We enrolled HIV-infected, virologically suppressed adults with 2-class to 3-class drug resistance and at least 2 prior regimen failures into this phase 3, open-label, randomized study. The primary endpoint was the percentage of participants with HIV-1 RNA <50 copies per milliliter at week 24 [Food and Drug Administration (FDA) snapshot algorithm]. RESULTS:: For 135 participants [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV), n = 89; baseline regimen, n = 46], most of whom were taking a median of 5 tablets/d, simplification to E/C/F/TAF plus DRV was noninferior to continuation of baseline regimens at week 24 (plasma HIV-1 RNA <50 copies per milliliter: 96.6% vs. 91.3%, difference 5.3%, 95.001% CI: −3.4% to 17.4%). E/C/F/TAF plus DRV met prespecified criteria for noninferiority and superiority at week 48 for the same outcome. E/C/F/TAF plus DRV was well tolerated and had an improved renal safety profile compared with baseline regimens, with statistically significant differences between groups in quantitative total proteinuria and markers of proximal tubular proteinuria. Compared with baseline regimens, participants who switched to E/C/F/TAF plus DRV reported higher mean treatment satisfaction scale total scores and fewer days with missed doses. CONCLUSIONS:: This study demonstrated that regimen simplification from a 5-tablet regimen to the 2-tablet, once-daily combination of E/C/F/TAF plus DRV has durable maintenance of virologic suppression and improvements in specific markers of renal safety. Such a strategy may lead to greater adherence and improved quality of life.
source
subjectClinical Science ; Hiv ; Regimen Simplification ; Tenofovir Alafenamide ; Darunavir;
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutOvid.html$$EView_Wolters_Kluwer_Health,_Lippincott,_Williams_&_Wilkins_Copyright_Statement
search
creatorcontrib
0Huhn, D, Gregory
1Tebas, M, Pablo
2Gallant, W, Joel
3Wilkin, W, Timothy
4Cheng, W, Andrew
5Yan, W, Mingjin
6Zhong, W, Lijie
7Callebaut, W, Christian
8Custodio, W, Joseph
9Fordyce, W, Marshall
10Das, W, Moupali
11McCallister, W, Scott
titleA Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
descriptionBACKGROUND:: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated with lower adherence and potential resistance development. METHODS:: We enrolled HIV-infected, virologically suppressed adults with 2-class to 3-class drug resistance and at least 2 prior regimen failures into this phase 3, open-label, randomized study. The primary endpoint was the percentage of participants with HIV-1 RNA <50 copies per milliliter at week 24 [Food and Drug Administration (FDA) snapshot algorithm]. RESULTS:: For 135 participants [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV), n = 89; baseline regimen, n = 46], most of whom were taking a median of 5 tablets/d, simplification to E/C/F/TAF plus DRV was noninferior to continuation of baseline regimens at week 24 (plasma HIV-1 RNA <50 copies per milliliter: 96.6% vs. 91.3%, difference 5.3%, 95.001% CI: −3.4% to 17.4%). E/C/F/TAF plus DRV met prespecified criteria for noninferiority and superiority at week 48 for the same outcome. E/C/F/TAF plus DRV was well tolerated and had an improved renal safety profile compared with baseline regimens, with statistically significant differences between groups in quantitative total proteinuria and markers of proximal tubular proteinuria. Compared with baseline regimens, participants who switched to E/C/F/TAF plus DRV reported higher mean treatment satisfaction scale total scores and fewer days with missed doses. CONCLUSIONS:: This study demonstrated that regimen simplification from a 5-tablet regimen to the 2-tablet, once-daily combination of E/C/F/TAF plus DRV has durable maintenance of virologic suppression and improvements in specific markers of renal safety. Such a strategy may lead to greater adherence and improved quality of life.
general
010.1097/QAI.0000000000001193
1Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
2Lippincott Williams & Wilkins - Journals
sourceidovid
recordidovid10.1097/QAI.0000000000001193
issn
01525-4135
115254135
rsrctypearticle
creationdate2017
addtitleJAIDS Journal of Acquired Immune Deficiency Syndromes
searchscopeovid
scopeovid
lsr30VSR-Enriched:[subject, eissn, date, pqid]
sort
titleA Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
authorHuhn, D., Gregory ; Tebas, M., Pablo ; Gallant, W., Joel ; Wilkin, W., Timothy ; Cheng, W., Andrew ; Yan, W., Mingjin ; Zhong, W., Lijie ; Callebaut, W., Christian ; Custodio, W., Joseph ; Fordyce, W., Marshall ; Das, W., Moupali ; Mccallister, W., Scott
creationdate20170200
facets
frbrgroupid5023048369390504303
frbrtype5
creationdate2017
collectionLippincott Williams & Wilkins Journals (Wolters Kluwer Health)
prefilterarticles
rsrctypearticles
creatorcontrib
0Huhn, D., Gregory
1Tebas, M., Pablo
2Gallant, W., Joel
3Wilkin, W., Timothy
4Cheng, W., Andrew
5Yan, W., Mingjin
6Zhong, W., Lijie
7Callebaut, W., Christian
8Custodio, W., Joseph
9Fordyce, W., Marshall
10Das, W., Moupali
11Mccallister, W., Scott
jtitleJAIDS Journal of Acquired Immune Deficiency Syndromes
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Huhn
1Tebas
2Gallant
3Wilkin
4Cheng
5Yan
6Zhong
7Callebaut
8Custodio
9Fordyce
10Das
11McCallister
aufirst
0Gregory
1Pablo
2Joel
3Timothy
4Andrew
5Mingjin
6Lijie
7Christian
8Joseph
9Marshall
10Moupali
11Scott
auinitm
0D.
1M.
2W.
au
0Huhn, D., Gregory
1Tebas, M., Pablo
2Gallant, W., Joel
3Wilkin, W., Timothy
4Cheng, W., Andrew
5Yan, W., Mingjin
6Zhong, W., Lijie
7Callebaut, W., Christian
8Custodio, W., Joseph
9Fordyce, W., Marshall
10Das, W., Moupali
11Mccallister, W., Scott
atitleA Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
jtitleJAIDS Journal of Acquired Immune Deficiency Syndromes
risdate201702
volume74
issue2
spage193
epage200
pages193-200
issn1525-4135
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUND:: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated with lower adherence and potential resistance development. METHODS:: We enrolled HIV-infected, virologically suppressed adults with 2-class to 3-class drug resistance and at least 2 prior regimen failures into this phase 3, open-label, randomized study. The primary endpoint was the percentage of participants with HIV-1 RNA <50 copies per milliliter at week 24 [Food and Drug Administration (FDA) snapshot algorithm]. RESULTS:: For 135 participants [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV), n = 89; baseline regimen, n = 46], most of whom were taking a median of 5 tablets/d, simplification to E/C/F/TAF plus DRV was noninferior to continuation of baseline regimens at week 24 (plasma HIV-1 RNA <50 copies per milliliter: 96.6% vs. 91.3%, difference 5.3%, 95.001% CI: −3.4% to 17.4%). E/C/F/TAF plus DRV met prespecified criteria for noninferiority and superiority at week 48 for the same outcome. E/C/F/TAF plus DRV was well tolerated and had an improved renal safety profile compared with baseline regimens, with statistically significant differences between groups in quantitative total proteinuria and markers of proximal tubular proteinuria. Compared with baseline regimens, participants who switched to E/C/F/TAF plus DRV reported higher mean treatment satisfaction scale total scores and fewer days with missed doses. CONCLUSIONS:: This study demonstrated that regimen simplification from a 5-tablet regimen to the 2-tablet, once-daily combination of E/C/F/TAF plus DRV has durable maintenance of virologic suppression and improvements in specific markers of renal safety. Such a strategy may lead to greater adherence and improved quality of life.
pubCopyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
doi10.1097/QAI.0000000000001193
eissn19447884
date2017-02-01